
What smart money is saying about Abbott Laboratories
5 funds in our archive have pitched Abbott Laboratories — most recently Acatis in August 2026.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q3 2026, 6 fund letters reported a position in Abbott Laboratories — 1 opened or added to the position, 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 0 | 0 | 0 | 1 |
| Q2 2026 | 6 | 1 | 2 | 0 |
| Q1 2026 | 0 | 0 | 0 | 3 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 6 positions · 3 moves
- New positionMatrix Asset Advisors Capital Markets CommentaryJune 2026
“During the quarter, we started new partial positions in Abbott Laboratories (ABT) and McDonald’s (MCD).”
Abbott Laboratories “The leading individual Portfolio detractors during the quarter were Abbott Laboratories (ABT) and Broadridge Financial Solutions (BR).”
Abbott Laboratories- June 2026
“Chevron was negatively impacted by a U.S.-Iran memorandum of understanding that reopened tanker traffic through the Strait of Hormuz, easing global oil supply constraints and sending oil prices down 31% during the quarter amid ongoing longer-term negotiations. Abbott Laboratories, a manufacturer of diagnostic products, nutritional products and medical devices, reported slightly lower growth expectations from its legacy businesses, including disruptions in the Middle East due to the ongoing Iran conflict and a weaker flu season that led to lower than expected diagnostics growth.”
Abbott Laboratories “Abbott Laboratories, a manufacturer of diagnostic products, nutritional products and medical devices, reported slightly lower growth expectations from its legacy businesses, including disruptions in the Middle East due to the ongoing Iran conflict, and a weaker flu season that led to lower than expected diagnostics growth.”
Abbott Laboratories- June 2026
“Seven positions were eliminated from the portfolio during the quarter.”
Abbott Laboratories - ExitedBurke Wealth Management Focused Growth StrategyJune 2026
“Q2 PORTFOLIO ACTIVITY The second quarter was an active trading quarter in our Focused Growth portfolio. We sold our positions in Abbott Labs and Lowe’s, added new positions in Eaton and Apollo, trimmed back rocket ship Micron twice for risk management purposes and used share price weakness as an opportunity to bolster our weightings in Intuitive Surgical, Meta, Service Now and Uber.”
Abbott Laboratories
Fund coverage · 5 theses
- AcatisAugust 2026
Abbott Laboratories is a diversified health care leader with recurring growth, competitive advantages and an attractive valuation.
Read the full thesis - The Davenport FundsMarch 2026
Abbott Laboratories is a diversified healthcare company with an expanded diagnostics market, accelerating growth guidance, and insider buying.
Read the full thesis - Alpha Wealth FundsMarch 2026
Abbott Laboratories is a diversified healthcare 'Dividend King' with insider-supported value and upside from Exact Sciences’ MCED integration.
Read the full thesis - Bell Global Equities FundJanuary 2026
Abbott Laboratories is a diversified medtech leader with catalysts in Libre and PFA, enhanced oncology diagnostics, and an attractive entry after de-rating.
Read the full thesis - Parnassus Value Select ETFDecember 2025
Abbott Laboratories offers durable growth from leadership in diabetes, heart health, and electrophysiology, supported by innovation and a diversified global model.
Read the full thesis
Read every full thesis on Abbott Laboratories
Unlock all 5 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→